Incyte pockets $60m for Jakavi reimbursement
This article was originally published in Scrip
Executive Summary
Incyte has landed a $60m milestone payment from Novartis after myelofibrosis treatment Jakavi (ruxolitinib) won positive reimbursement decisions in Germany, France and Italy. The achievement of these reimbursement decisions also triggers the payment of US royalties from Incyte to Novartis.